Setmelanotide
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm · Phase 3 · Completed · Enrollment 52
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Pivotal Cohort: week 52 -5.21%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.